Cargando…

CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer due to its lack of treatment options. Patients with TNBC frequently develop resistance to chemotherapy. As epigenetic-based antineoplastic drugs, histone deacetylase inhibitors (HDACis) have achieved particular efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Xin-le, Du, Jun, Zheng, Ya-dan, Dai, Jia-jing, Lin, Su-wen, Zhang, Bing-yue, Zhong, Fu-bo, Lin, Zhe-guang, Jiang, Shu-qi, Wei, Wei, Fang, Zheng-yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075662/ https://www.ncbi.nlm.nih.gov/pubmed/33959656 http://dx.doi.org/10.1155/2021/5089371

Ejemplares similares

Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
por: Zhang, Changde, et al.
Publicado: (2019)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

Repurposing Belinostat for Alleviation of Atopic Dermatitis
por: Quah, Shan, et al.
Publicado: (2021)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model
por: Kaczmarek, Jessica V., et al.
Publicado: (2021)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
por: Allen, Pamela B, et al.
Publicado: (2018)

CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer
por: Liang, Yuan-ke, et al.
Publicado: (2021)

Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer
por: Hu, Xiao-Qing, et al.
Publicado: (2017)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Monitoring the effect of belinostat in solid tumors by H4 acetylation
por: MARQUARD, LENA, et al.
Publicado: (2008)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014)

New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
por: Reimer, Peter
Publicado: (2015)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Preclinical efficacy of belinostat in combination with zidovudine in adult T-cell leukemia-lymphoma
por: Toomey, Ngoc, et al.
Publicado: (2015)

Cloning and Expression Analysis of HAT1 and HDAC1 in the Testes of Mature Yaks and Their Sterile Hybrids
por: Sun, Shijie, et al.
Publicado: (2022)

TTK is a favorable prognostic biomarker for triple-negative breast cancer survival
por: Xu, Qianqian, et al.
Publicado: (2016)

Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
por: Menbari, Mohammad-Nazir, et al.
Publicado: (2020)

Nanosecond Pulsed Electric Field Induces an Antitumor Effect in Triple-Negative Breast Cancer via CXCL9 Axis Dependence in Mice
por: Xu, Zhentian, et al.
Publicado: (2023)

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer
por: Lian, Bi, et al.
Publicado: (2020)

17-AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA-MB-231 breast cancer cells
por: Zuo, Yu, et al.
Publicado: (2020)

Cloning, expression and characterization of ferret CXCL10
por: Danesh, Ali, et al.
Publicado: (2008)

VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
por: Cao, Xi, et al.
Publicado: (2021)

CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer
por: Li, Enhao, et al.
Publicado: (2021)

Zinc Favors Triple-Negative Breast Cancer’s Microenvironment Modulation and Cell Plasticity
por: Vogel-González, Marina, et al.
Publicado: (2021)

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
por: Li, Mengxing, et al.
Publicado: (2021)

HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer
por: Zhu, Mengdi, et al.
Publicado: (2022)

Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling
por: Tsai, Yu-Chieh, et al.
Publicado: (2023)

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
por: Reimer, Peter, et al.
Publicado: (2013)

Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
por: Kong, Li R., et al.
Publicado: (2017)

Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells
por: Isono, Makoto, et al.
Publicado: (2016)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme
por: Xia, Xiangping, et al.
Publicado: (2019)

CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients
por: Zeng, Yan-Li, et al.
Publicado: (2016)

ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer
por: Jung, Hae-Yun, et al.
Publicado: (2023)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
por: Buckley, Michael T, et al.
Publicado: (2007)

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2013)

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
por: Takebe, Naoko, et al.
Publicado: (2019)

Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC)
por: Chuan, Tian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q4ccbtp4a8n42g79pc6tsse2vj